Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by ASCT for Newly Diagnosed Multiple Myeloma
NCT01255514Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Oct 2008
- Primary completion
- Dec 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Yonsei University. Primary endpoint: Complete Response plus near Complete Response. Started Oct 2008; status: completed.
02
Drugs
dexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01255514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255514.